title: Efficacy and toxicity of concurrent chemoradiotherapy in patients with advanced oropharyngeal squamous cell carcinoma.
abstract: OBJECTIVE
  The aim of this study was to evaluate the feasibility and toxicity of concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin (CDDP) and 5-fluorouracil (5-FU) (TPF regimen) or with CDDP, 5-FU, methotrexate and leucovorin (PFML regimen) in previously untreated patients with advanced oropharyngeal squamous cell carcinoma (SCC).
  
  
  METHODS
  Fifty-six eligible patients with stage III or IV oropharyngeal SCC were treated with CCRT. Forty-four patients were men and 12 were women, and the average age of the patients was 58.8 years (range, 37-72 years). In the TPF group, patients received CCRT with the TPF regimen [docetaxel (50 mg/m(2), day 1), CDDP (60 mg/m(2), day 4) and a continuous 5-FU infusion (600 mg/m(2)/day, days 1-5)]. In the PFML group, patients received CCRT with the PFML regimen [CDDP (60 mg/m(2), day 4), a continuous 5-FU infusion (600 mg/m(2)/day, days 1-5), methotrexate (30 mg/m(2), day 1) and leucovorin (10 mg/m(2)/day, days 1-5)]. The total radiation dose was between 66.6 and 70.2 Gy.
  
  
  RESULTS
  The overall 5-year survival rate was 64.6% in all patients, 68.6% in the resectable group and 47.4% in the unresectable group. The 5-year disease-specific survival rate was 72.2% in all patients, 78.1% in the resectable group and 47.7% in the unresectable group. Regarding clinical stage, the 5-year disease-specific survival rates were 91% in stage III, 72% in stage IVa and 44% in stage IVb.
  
  
  CONCLUSIONS
  CCRT with TPF or PFML regimen for advanced oropharyngeal SCC is tolerable and effective, especially in patients with resectable disease.
authors.affiliation: Department of Otolaryngology, and Head and Neck Surgery, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan. watamaki@yokohama-cu.ac.jp
authors.forename: Makiko
authors.initials: M
authors.lastname: Mori
authors.forename: Mamoru
authors.initials: M
authors.lastname: Tsukuda
authors.forename: Hideki
authors.initials: H
authors.lastname: Matsuda
authors.forename: Choichi
authors.initials: C
authors.lastname: Horiuchi
authors.forename: Takahide
authors.initials: T
authors.lastname: Taguchi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Takahashi
authors.forename: Goshi
authors.initials: G
authors.lastname: Nishimura
authors.forename: Masanori
authors.initials: M
authors.lastname: Komatsu
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Niho
authors.forename: Naoko
authors.initials: N
authors.lastname: Sakuma
authors.forename: Asako
authors.initials: A
authors.lastname: Miyakoshi
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Isono
authors.forename: Sayaka
authors.initials: S
authors.lastname: Iwahana
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009959:Oropharyngeal Neoplasms / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate